Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ARID1A_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ARID1A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ARID1A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ARID1A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ARID1A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ARID1A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ARID1A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ARID1A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ARID1A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00063382 | Prostate | BPH | chromatin remodeling | 62/3107 | 255/18723 | 9.47e-04 | 5.97e-03 | 62 |
GO:0031958 | Prostate | BPH | corticosteroid receptor signaling pathway | 8/3107 | 15/18723 | 1.21e-03 | 7.41e-03 | 8 |
GO:00305205 | Prostate | BPH | intracellular estrogen receptor signaling pathway | 17/3107 | 54/18723 | 5.09e-03 | 2.40e-02 | 17 |
GO:00063374 | Prostate | BPH | nucleosome disassembly | 8/3107 | 18/18723 | 5.17e-03 | 2.43e-02 | 8 |
GO:00314985 | Prostate | BPH | chromatin disassembly | 8/3107 | 20/18723 | 1.09e-02 | 4.50e-02 | 8 |
GO:004854519 | Prostate | Tumor | response to steroid hormone | 118/3246 | 339/18723 | 4.46e-15 | 6.94e-13 | 118 |
GO:007138317 | Prostate | Tumor | cellular response to steroid hormone stimulus | 76/3246 | 204/18723 | 7.73e-12 | 6.16e-10 | 76 |
GO:003052217 | Prostate | Tumor | intracellular receptor signaling pathway | 81/3246 | 265/18723 | 7.65e-08 | 2.14e-06 | 81 |
GO:002241118 | Prostate | Tumor | cellular component disassembly | 121/3246 | 443/18723 | 8.10e-08 | 2.23e-06 | 121 |
GO:003051815 | Prostate | Tumor | intracellular steroid hormone receptor signaling pathway | 44/3246 | 116/18723 | 1.02e-07 | 2.72e-06 | 44 |
GO:003052115 | Prostate | Tumor | androgen receptor signaling pathway | 23/3246 | 44/18723 | 1.35e-07 | 3.45e-06 | 23 |
GO:004340115 | Prostate | Tumor | steroid hormone mediated signaling pathway | 48/3246 | 136/18723 | 3.53e-07 | 7.87e-06 | 48 |
GO:000632514 | Prostate | Tumor | chromatin organization | 104/3246 | 409/18723 | 2.02e-05 | 2.62e-04 | 104 |
GO:000975514 | Prostate | Tumor | hormone-mediated signaling pathway | 56/3246 | 190/18723 | 2.39e-05 | 3.00e-04 | 56 |
GO:000635412 | Prostate | Tumor | DNA-templated transcription, elongation | 31/3246 | 91/18723 | 8.58e-05 | 8.53e-04 | 31 |
GO:000636812 | Prostate | Tumor | transcription elongation from RNA polymerase II promoter | 25/3246 | 69/18723 | 1.33e-04 | 1.23e-03 | 25 |
GO:003298413 | Prostate | Tumor | protein-containing complex disassembly | 61/3246 | 224/18723 | 1.36e-04 | 1.26e-03 | 61 |
GO:003298614 | Prostate | Tumor | protein-DNA complex disassembly | 10/3246 | 20/18723 | 8.21e-04 | 5.54e-03 | 10 |
GO:00429211 | Prostate | Tumor | glucocorticoid receptor signaling pathway | 8/3246 | 14/18723 | 8.99e-04 | 5.96e-03 | 8 |
GO:00319581 | Prostate | Tumor | corticosteroid receptor signaling pathway | 8/3246 | 15/18723 | 1.63e-03 | 9.79e-03 | 8 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARID1A | SNV | Missense_Mutation | novel | c.5834N>T | p.Pro1945Leu | p.P1945L | O14497 | protein_coding | tolerated(0.09) | probably_damaging(0.997) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
ARID1A | SNV | Missense_Mutation | | c.6427N>T | p.Arg2143Cys | p.R2143C | O14497 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
ARID1A | SNV | Missense_Mutation | | c.5747N>G | p.Ser1916Cys | p.S1916C | O14497 | protein_coding | tolerated(0.29) | benign(0.007) | TCGA-A8-A07I-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
ARID1A | SNV | Missense_Mutation | | c.2644N>T | p.Gly882Trp | p.G882W | O14497 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
ARID1A | SNV | Missense_Mutation | novel | c.3331N>A | p.Glu1111Lys | p.E1111K | O14497 | protein_coding | deleterious(0.03) | probably_damaging(0.989) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ARID1A | SNV | Missense_Mutation | | c.3819G>A | p.Met1273Ile | p.M1273I | O14497 | protein_coding | deleterious(0.03) | benign(0.065) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ARID1A | SNV | Missense_Mutation | novel | c.2663G>A | p.Gly888Glu | p.G888E | O14497 | protein_coding | deleterious(0.04) | possibly_damaging(0.722) | TCGA-AR-A1AI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
ARID1A | SNV | Missense_Mutation | novel | c.1388G>T | p.Gly463Val | p.G463V | O14497 | protein_coding | tolerated_low_confidence(0.05) | possibly_damaging(0.593) | TCGA-AR-A24X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ARID1A | SNV | Missense_Mutation | | c.3715N>A | p.Ala1239Thr | p.A1239T | O14497 | protein_coding | tolerated(0.12) | benign(0.214) | TCGA-BH-A0E7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ARID1A | SNV | Missense_Mutation | | c.2542N>T | p.Pro848Ser | p.P848S | O14497 | protein_coding | tolerated(0.12) | benign(0.091) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |